Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | VNN1 | O95497 | 7/20 | 0.37 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21016962 | 0.86 | ACACB (0.38) | POLBGAAKDM4EL3MBTL1HPGD | |
| SCHEMBL21017084 | 0.86 | KDM4E (0.54) | POLBGAAKDM4EL3MBTL1HPGD | |
| SCHEMBL21016981 | 0.85 | ACACB (0.42) | POLBKDM4EL3MBTL1ALDH1A1VNN1 | |
| SCHEMBL21017082 | 0.83 | HCAR3 (0.49) | POLBGAAKDM4EHPGDDEGS1 | |
| SCHEMBL23768190 | 0.74 | GPR55 (0.35) | POLBGAAKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL21016712 | 0.74 | VNN1 (0.37) | POLBGAAALDH1A1VNN1DEGS1 | |
| SCHEMBL23768084 | 0.73 | POLB (0.54) | POLBGAAKDM4EL3MBTL1HPGD | |
| SCHEMBL8532930 | 0.72 | KCNN4 (0.52) | GAAL3MBTL1HPGDALDH1A1VNN1 | |
| SCHEMBL2054678 | 0.72 | DEGS1 (0.54) | POLBGAAALDH1A1DEGS1LMNA | |
| SCHEMBL21016975 | 0.71 | HCAR3 (0.47) | POLBGAAKDM4EL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787779-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787779-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-20210253554-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253554-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | TYK2, JAK3, JAK2 | POLB 3486/4885GAA 4444/4885KDM4E 1208/4885 |
| US-11787779-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | TYK2, JAK3, JAK2 | POLB 3486/4885GAA 4444/4885KDM4E 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.